Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation
May 3, 2016 7:27 AM EDTCredit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.
MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More
Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play
May 2, 2016 7:19 AM EDTStifel analyst, Thomas Shrader, tries to sort through the buyout hype surrounding Medivation (NASDAQ: MDVN) in a note this morning. Recent news reports make it pretty clear Medivation is in play but like many biotechnology stories the value of the company is based on many assumptions. His takeaway is that a fair price would be $66 and possibly as high as $85... More
Sanofi (SNY) Issues Commentary on Medivation's (MDVN) Rejection of Takeover Proposal; Remains Committed to Combination
April 29, 2016 9:06 AM EDTSanofi (NYSE: SNY) commented on Medivation, Inc.'s (Nasdaq: MDVN) rejection of Sanofi's non-binding all-cash proposal to acquire Medivation for $52.50 per share:
Combining Sanofi and... More
